Investors & Media

There are currently no events to display.

Company Profile

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs – such as children and adults with spinal muscular atrophy (SMA). We created SPINRAZA®(nusinersen)* and are proud to have brought new hope to the SMA community by developing the first and only approved treatment for this disease. 

Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 drugs with the potential to treat patients with cardiovascular disease, rare diseases, neurological diseases, infectious diseases and cancer. We created TEGSEDI™ (inotersen) the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin (TTR) amyloidosis (ATTR) in adult patients that our affiliate Akcea Therapeutics is commercializing. Together with Akcea, we are also bringing new medicines to patients with cardiometabolic lipid disorders.

*Spinraza is marketed by Biogen.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast
Webcast scheduled for Wednesday, February 27 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 13, 2019 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27 th at 11:30 a.m.
Toggle Summary First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First of 4+ Ionis programs expected to advance to pivotal studies this year Ionis earns $35 million milestone payment CARLSBAD, Calif. , Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that its partner Roche , also
Toggle Summary Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Jan. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that Management will present a Company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m.
Toggle Summary Ionis Announces Plans for Management Transitions in 2020
CARLSBAD, Calif. , Dec. 20, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its Board of Directors announced today that, effective January 2020 , Ionis' founder and CEO, Stanley T. Crooke , M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of

Upcoming Events

More >>
Date Event Details
Summary Toggle 02/27/19 11:30 am EST
Summary Toggle 06/15/19 12:15 pm CEST

Bridging The Gap: Translating Genomic Discovery Into Human Therapeutics 

 

Bridging the Gap

 

Location:
European Society of Human Genetics Annual Conference 
Swedish Exhibition & Congress Center
Mässans Gata/Korsvägen
412 94 Göteborg, Sweden
 

 - Registration for the ESHG conference is required
 - The first 50 registrants for the Bridging The Gap corporate Satellite Symposium will receive a free gift
 - Registration link coming soon
 - Lunch will be provided
 

Location

European Society of Human Genetics Annual Conference

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright West LLC. Minimum 15 minutes delayed.

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.